MyMetabolon Login
© 2021 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Quality Assurance
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Microbiome
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
    • Publications
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
    • Publications
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data

Bile acid quantification provides insight into the mechanism of action for the treatment of NASH

inBiomarkers, Drug Development

Targeted analysis supports the development of NASH treatment.

Nonalcoholic steatohepatitis (NASH) is the advanced, progressive form of nonalcoholic fatty liver disease (NAFLD). Both conditions are hepatic diseases associated with metabolic and cardiovascular disorders like obesity, hypertension, and type 2 diabetes (T2D).

Patients with NASH are at an increased risk of mortality compared with the NAFLD population. Therefore, there is a significant unmet need for therapeutics that can effectively manage or reverse the disease progression. Drug developers have the challenge of identifying effective treatments to support this patient population that often represents complex disease manifestations. Because of the diverse pathophysiology of NASH, various mechanisms of action are under investigation in clinical studies.

Targeted Assays

Delivering Absolute Quantification for Research and Biomarker Analysis

Our readily available or custom developed quantitative assays help you achieve your research and biomarker validation objectives with precise and fully validated methods.

See how Metabolon’s expanded suite of 45+ ready-to-run targeted assays can meet your needs.

Previous studies have shown that elevated bile acid concentrations are associated with the presence and severity of liver disorders. Given the link between bile acids and metabolic regulation, there is growing interest in understanding how bile acid dysregulation may contribute to NASH pathogenesis and progression.

Stages of Liver Disease

A new study published in the Journal of Hepatology Reports leveraged targeted analysis approaches to evaluate the effects of Pegbelfermin (PGBF) treatment on bile acid metabolism by measuring serum bile acid concentrations in a phase 2a study in patients with NASH. To further explore potential mechanisms underlying these observations, the effect of PGBF on the gut microbiome was evaluated using stool samples from a phase 1 study in healthy overweight or obese adults. Read more about how this study leveraged quantitative biomarker analysis to arrive at the results that revealed a valuable mechanism of action to support insight into a potential therapeutic: https://www.jhep-reports.eu/article/S2589-5559(21)00168-3/fulltext#secsectitle0150

The approach to understanding the mechanism of action of therapeutics offers a pivotal opportunity to develop new drug development and clinical trial models to meet patient needs across various chronic and acute diseases.

Learn how Metabolon can help accelerate your research, contact us today.

Back to the Blog
  • The Scientist Magazine: Doctors Treat Girl’s Genetic Disorder with Repurposed Drug
    Previous PostThe Scientist Magazine: Doctors Treat Girl’s Genetic Disorder with Repurposed Drug
  • Next PostLeading medical centers leverage metabolomics to better understand the impact of lactation on birth and maternal outcomes
    The Scientist Magazine: Doctors Treat Girl’s Genetic Disorder with Repurposed Drug

Related Posts

Event: Precision Medicine World Conference (PMWC)
Events

Event: Precision Medicine World Conference (PMWC)

Webinar: Integrated Multiomic Analysis for Disease
Events

Webinar: Integrated Multiomic Analysis for Disease

Metabolomics in drug discovery: The missing piece for multi-omics data
Events

Metabolomics in drug discovery: The missing piece for multi-omics data

How Metabolomics Can Raise the Bar in Drug Development
Drug Development Working with Metabolon

How Metabolomics Can Raise the Bar in Drug Development

Metabolon Announces Chief Financial Officer Transition
Company News

Metabolon Announces Chief Financial Officer Transition

Lunch and Learn: Applications of Metabolomics in Microbiome Research
Events

Lunch and Learn: Applications of Metabolomics in Microbiome Research

Metabolon to Power Metabolomic Enriched Population Health Studies at FinnGen
Company News

Metabolon to Power Metabolomic Enriched Population Health Studies at FinnGen

Overcoming the Limitations of Mass Spectrometry Across Datasets
Blog Capabilities Working with Metabolon

Overcoming the Limitations of Mass Spectrometry Across Datasets

Leading medical centers leverage metabolomics to better understand the impact of lactation on birth and maternal outcomes
Company News

Leading medical centers leverage metabolomics to better understand the impact of lactation on birth and maternal outcomes

Bile acid quantification provides insight into the mechanism of action for the treatment of NASH
Biomarkers Drug Development

Bile acid quantification provides insight into the mechanism of action for the treatment of NASH

Metabolomics

  • About Metabolomics
  • Our Process
  • Technology & Knowledgebase
  • Quality Assurance
  • Setting the Standard: The 4Cs
  • Insights & Discoveries

Solutions

  • Products & Services
  • By Research & Development Phase
  • By Therapeutic Area
  • By Sector

Insights

  • Our Latest Insights
  • Blog
  • News & Events
  • Publications

Resources

  • Resource Library
  • Client Stories
  • COVID-19

Company

  • About Us
  • Working With Us (FAQ)
  • Leadership
  • Careers
  • Strategic Partnering
  • News & Events
  • Contact Us
Metabolon - Logo - Enlightening Life

Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

© 2022 Metabolon, Inc. All rights reserved. Privacy & Terms

in
Copy